JP2003520195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520195A5 JP2003520195A5 JP2000617919A JP2000617919A JP2003520195A5 JP 2003520195 A5 JP2003520195 A5 JP 2003520195A5 JP 2000617919 A JP2000617919 A JP 2000617919A JP 2000617919 A JP2000617919 A JP 2000617919A JP 2003520195 A5 JP2003520195 A5 JP 2003520195A5
- Authority
- JP
- Japan
- Prior art keywords
- cooh
- alkyl
- substituted
- oxide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- -1 heteroaryl compound Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000815 N-oxide group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31228499A | 1999-05-14 | 1999-05-14 | |
| US09/312,284 | 1999-05-14 | ||
| US37402899A | 1999-08-13 | 1999-08-13 | |
| US09/374,028 | 1999-08-13 | ||
| PCT/US2000/011756 WO2000069459A1 (en) | 1999-05-14 | 2000-05-01 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008244928A Division JP2009120583A (ja) | 1999-05-14 | 2008-09-24 | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003520195A JP2003520195A (ja) | 2003-07-02 |
| JP2003520195A5 true JP2003520195A5 (enExample) | 2008-11-13 |
Family
ID=26978320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617919A Pending JP2003520195A (ja) | 1999-05-14 | 2000-05-01 | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
| JP2008244928A Pending JP2009120583A (ja) | 1999-05-14 | 2008-09-24 | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008244928A Pending JP2009120583A (ja) | 1999-05-14 | 2008-09-24 | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20020012663A1 (enExample) |
| EP (2) | EP2042194A3 (enExample) |
| JP (2) | JP2003520195A (enExample) |
| KR (1) | KR20020000223A (enExample) |
| CN (1) | CN1200734C (enExample) |
| AU (1) | AU782994C (enExample) |
| BG (1) | BG106110A (enExample) |
| BR (1) | BR0010524A (enExample) |
| CA (1) | CA2373815A1 (enExample) |
| CZ (1) | CZ20014083A3 (enExample) |
| EE (1) | EE200100603A (enExample) |
| HK (1) | HK1047236A1 (enExample) |
| HU (1) | HUP0201480A3 (enExample) |
| IL (1) | IL146480A0 (enExample) |
| MX (1) | MXPA01011632A (enExample) |
| NO (1) | NO20015546L (enExample) |
| PL (1) | PL365999A1 (enExample) |
| RU (1) | RU2294761C2 (enExample) |
| SK (1) | SK16522001A3 (enExample) |
| WO (1) | WO2000069459A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| EP2042194A3 (en) * | 1999-05-14 | 2009-04-22 | Imclone Systems, Inc. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| AU9500201A (en) * | 2000-08-09 | 2002-02-18 | Imclone Systems Inc | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| EP1236474A1 (en) * | 2001-02-26 | 2002-09-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Negative regulation of epidermal growth factor receptor activity by Mig-6 |
| US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| CA2445898A1 (en) | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
| AU2002315306B2 (en) * | 2001-05-08 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
| KR100719624B1 (ko) * | 2001-05-18 | 2007-05-21 | 석정철 | 시각장애인을 위한 접착형 점자유도블록 및점자유도블록의 접착방법 |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2002319402B2 (en) * | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| AU2003219029B2 (en) * | 2002-03-08 | 2008-09-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V | Use of EGFR transactivation inhibitors in human cancer |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
| JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| JPWO2004060400A1 (ja) * | 2003-01-06 | 2006-05-11 | 那波 宏之 | 上皮成長因子受容体を分子標的とする抗精神病薬 |
| WO2004073601A2 (en) * | 2003-02-21 | 2004-09-02 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| WO2005001053A2 (en) | 2003-06-09 | 2005-01-06 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist |
| EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| JPWO2005027970A1 (ja) * | 2003-09-24 | 2007-11-15 | 協和醗酵工業株式会社 | 癌治療用医薬 |
| ES2372694T3 (es) * | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| WO2005090407A1 (en) * | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| HRP20090495T1 (hr) * | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
| UA88008C2 (en) | 2004-04-09 | 2009-09-10 | Чугей Сейяку Кабусики Кайся | Water-soluble prodrugs |
| RU2006146612A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
| BRPI0511780A (pt) * | 2004-06-03 | 2008-01-15 | Hoffmann La Roche | tratamento com oxoliplatina e um inibidor de egrf |
| BRPI0511800A (pt) * | 2004-06-03 | 2008-01-15 | Hoffmann La Roche | tratamento com irinotecano (cpt-11) e um inibidor de egfr |
| KR100986945B1 (ko) * | 2004-06-03 | 2010-10-12 | 에프. 호프만-라 로슈 아게 | 젬시타빈 및 ｅｇｆｒ-억제제로의 치료 |
| US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
| US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
| US20060084691A1 (en) * | 2004-10-18 | 2006-04-20 | Bilal Piperdi | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
| US20070099856A1 (en) * | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| KR20080066039A (ko) * | 2005-10-19 | 2008-07-15 | 추가이 세이야쿠 가부시키가이샤 | 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제 |
| WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
| CN101454344A (zh) * | 2005-12-01 | 2009-06-10 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的非竞争性域抗体形式 |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| EP2338488A1 (en) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| KR100723641B1 (ko) * | 2006-06-07 | 2007-06-04 | 실버레이 주식회사 | 다중 조리가 가능한 솥 |
| US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
| WO2008046107A2 (en) * | 2006-10-13 | 2008-04-17 | The Regents Of The University Of California | Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface |
| EP2126127B1 (en) * | 2007-01-25 | 2016-09-28 | Dana-Farber Cancer Institute, Inc. | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| CA2680854C (en) * | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| NZ580530A (en) * | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| US9283276B2 (en) | 2007-08-14 | 2016-03-15 | Ludwig Institute For Cancer Research Ltd. | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof |
| EP2220222A4 (en) * | 2007-11-19 | 2011-10-12 | Univ California | NEW TEST FOR EGFR HEMMER |
| JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| US20110033453A1 (en) * | 2008-03-05 | 2011-02-10 | Carlos Garcia-Echeverria | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| EP2283020B8 (en) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
| JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 副腎皮質癌を治療するためのｏｓｉ−９０６の使用 |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| RU2457546C1 (ru) * | 2011-03-09 | 2012-07-27 | Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) | Способ моделирования аденокарциномы толстой кишки человека |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| EP3501546A3 (de) | 2011-04-21 | 2019-09-18 | Seattle Genetics, Inc. | Cystein-wirkstoff konjugate und ihre verwendung |
| CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
| WO2013055530A1 (en) | 2011-09-30 | 2013-04-18 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| KR20160130778A (ko) | 2014-02-28 | 2016-11-14 | 텐샤 세러퓨틱스 인코포레이티드 | 고인슐린혈증과 관련된 질환의 치료 |
| MX2016012285A (es) | 2014-03-24 | 2017-01-23 | Genentech Inc | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| CA3070342A1 (en) * | 2017-07-18 | 2019-01-24 | Kyowa Kirin Co., Ltd. | Anti-human ccr1 monoclonal antibody |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4186567A (en) * | 1977-04-18 | 1980-02-05 | Hitachi Metals, Ltd. | Ornament utilizing rare earth-cobalt magnet |
| US4510924A (en) * | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| US4846782A (en) | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| CA1341411C (en) | 1988-04-16 | 2002-12-17 | Lutz Riechmann | Method for producing fv fragments in eukaryotic cells |
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| JP3039802B2 (ja) * | 1989-07-06 | 2000-05-08 | ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア | 繊維芽細胞成長因子のための受容体 |
| US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5196446A (en) * | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
| SK281143B6 (sk) * | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| ATE255131T1 (de) * | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| PT1696031E (pt) * | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| JP3720353B2 (ja) * | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5550114A (en) * | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
| PL315941A1 (en) * | 1994-02-23 | 1996-12-09 | Pfizer | 4-heterocyclic substituted derivatives of quinazoline, methods of obtaining them and their application as anticarcinogenic agents |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| ES2191702T3 (es) * | 1994-03-17 | 2003-09-16 | Merck Patent Gmbh | Fv monocatenarios anti-egfr y anticuerpos anti-egfr. |
| US5656655A (en) | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
| US5869465A (en) * | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
| US5468754A (en) | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
| US5604233A (en) | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| JPH11507535A (ja) * | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| AU1441497A (en) * | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| US5925566A (en) * | 1996-06-06 | 1999-07-20 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
| US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
| US5914269A (en) * | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| EP2042194A3 (en) * | 1999-05-14 | 2009-04-22 | Imclone Systems, Inc. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| PL202369B1 (pl) * | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
| CA2422881A1 (en) * | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| WO2002045653A2 (en) * | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| US20040116330A1 (en) * | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| WO2002100348A2 (en) * | 2001-06-13 | 2002-12-19 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| AU2003219029B2 (en) * | 2002-03-08 | 2008-09-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V | Use of EGFR transactivation inhibitors in human cancer |
| DE60326226D1 (de) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom |
| EP1510221A4 (en) * | 2002-06-03 | 2009-04-29 | Mitsubishi Tanabe Pharma Corp | MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR |
| ES2533963T3 (es) * | 2002-10-10 | 2015-04-16 | Merck Patent Gmbh | Composiciones farmacéuticas dirigidas a receptores Erb-B1 |
| EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| PT1687338E (pt) * | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| RU2390353C2 (ru) * | 2004-02-12 | 2010-05-27 | Мерк Патент Гмбх | Высококонцентрированные жидкие композиции анти-egfr антител |
| TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| WO2005090407A1 (en) * | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
-
2000
- 2000-05-01 EP EP08015392A patent/EP2042194A3/en not_active Withdrawn
- 2000-05-01 EP EP00928671A patent/EP1218032A4/en not_active Withdrawn
- 2000-05-01 PL PL00365999A patent/PL365999A1/xx not_active IP Right Cessation
- 2000-05-01 AU AU46871/00A patent/AU782994C/en not_active Ceased
- 2000-05-01 MX MXPA01011632A patent/MXPA01011632A/es not_active Application Discontinuation
- 2000-05-01 KR KR1020017014494A patent/KR20020000223A/ko not_active Ceased
- 2000-05-01 HK HK02108768.1A patent/HK1047236A1/zh unknown
- 2000-05-01 WO PCT/US2000/011756 patent/WO2000069459A1/en not_active Ceased
- 2000-05-01 CA CA002373815A patent/CA2373815A1/en not_active Abandoned
- 2000-05-01 JP JP2000617919A patent/JP2003520195A/ja active Pending
- 2000-05-01 SK SK1652-2001A patent/SK16522001A3/sk unknown
- 2000-05-01 EE EEP200100603A patent/EE200100603A/xx unknown
- 2000-05-01 RU RU2001130771/14A patent/RU2294761C2/ru active
- 2000-05-01 CZ CZ20014083A patent/CZ20014083A3/cs unknown
- 2000-05-01 CN CNB008103216A patent/CN1200734C/zh not_active Expired - Fee Related
- 2000-05-01 BR BR0010524-4A patent/BR0010524A/pt not_active IP Right Cessation
- 2000-05-01 HU HU0201480A patent/HUP0201480A3/hu unknown
- 2000-05-01 IL IL14648000A patent/IL146480A0/xx unknown
-
2001
- 2001-04-24 US US09/840,146 patent/US20020012663A1/en not_active Abandoned
- 2001-11-13 NO NO20015546A patent/NO20015546L/no not_active Application Discontinuation
- 2001-11-14 BG BG106110A patent/BG106110A/bg unknown
- 2001-11-30 US US09/996,954 patent/US20030157104A1/en not_active Abandoned
-
2004
- 2004-12-20 US US11/018,950 patent/US20050112120A1/en not_active Abandoned
-
2008
- 2008-09-24 JP JP2008244928A patent/JP2009120583A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU97101665A (ru) | Замещенные производные хиназолина | |
| JP2020507589A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2005509622A5 (enExample) | ||
| JP2005505618A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2005511547A5 (enExample) | ||
| RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
| JP2005511531A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| JP2005511699A5 (enExample) | ||
| JP2004529114A5 (enExample) | ||
| RU2004111601A (ru) | Пиперидиновые производные и их применение в качестве модуляторов активности р ецепторов хемокина (в частности ccr5) | |
| JP2005508337A5 (enExample) | ||
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| JP2005538111A5 (enExample) | ||
| EE200000472A (et) | Kasvajavastased toimeained | |
| RU2005121908A (ru) | Производные зн-хиназолин-4-она | |
| JP2004523478A5 (enExample) | ||
| RU2003130644A (ru) | Производные ркарболина и их фармацевтическое применение против дипрессии и страха | |
| JP2005538974A5 (enExample) | ||
| RU2005128793A (ru) | Химические соединения | |
| JP2005533064A5 (enExample) | ||
| EA200400219A1 (ru) | Производные хинолина и их использование в качестве противоопухолевых средств |